Peripheral Arterial Disease Therapeutics Market by Treatment Type, Indication Stage, End-Users

List of Tables

The Peripheral Arterial Disease Therapeutics Market is projected to reach USD 8.55 billion by 2030 from USD 4.41 billion in 2022, at a CAGR of 8.62% during the forecast period.

Global Peripheral Arterial Disease Therapeutics Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 4.41 billion
Estimated Year Value [2023]	USD 4.75 billion
Forecast Year Value [2030]	USD 8.55 billion
CAGR (%)	8.62%

Peripheral Arterial Disease Therapeutics Market - IMG1

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Peripheral Arterial Disease Therapeutics Market.

Based on Treatment Type, market is studied across Medications and Surgical Treatments. The Medications is further studied across Antihypertensives, Naftidrofuryl Oxalate, and Statins. The Surgical Treatments is further studied across Angioplasty and Artery Bypass Graft. The Surgical Treatments is projected to witness significant market share during forecast period.

Based on Indication Stage, market is studied across Asymptomatic, Ischemic Rest Pain, Mild Claudication, Moderate/Severe Claudication, and Ulcers/Gangrene. The Moderate/Severe Claudication is projected to witness significant market share during forecast period.

Based on End-Users, market is studied across Hospitals and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Peripheral Arterial Disease Therapeutics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Peripheral Arterial Disease Therapeutics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Peripheral Arterial Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alucent Biomedical Inc., AnGes, Inc., AngioDynamics, Inc., ARCA biopharma, Inc., B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Helixmith Co., Ltd., Koninklijke Philips N.V., LeMaitre Vascular, Inc., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, REVA Medical, LLC, Terumo Corporation, Venturis Therapeutics, Inc., and W. L. Gore & Associates, Inc..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Peripheral Arterial Disease Therapeutics Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Peripheral Arterial Disease Therapeutics Market?

3. What is the competitive strategic window for identifying opportunities in the Peripheral Arterial Disease Therapeutics Market?

4. What are the latest technology trends and regulatory frameworks in the Peripheral Arterial Disease Therapeutics Market?

5. What is the market share of the leading vendors in the Peripheral Arterial Disease Therapeutics Market?

6. Which modes and strategic moves are suitable for entering the Peripheral Arterial Disease Therapeutics Market?

Product Code: MRR-69324464D2CB

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Peripheral Arterial Disease Therapeutics Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising incidences of peripheral arterial disease with an increasing geriatric population
  - 5.1.1.2. Increasing shift toward unhealthy lifestyles among people globally
  - 5.1.1.3. Growing preference for minimally invasive endovascular procedures
- 5.1.2. Restraints
  - 5.1.2.1. High cost associated with treatment of peripheral arterial disease
- 5.1.3. Opportunities
  - 5.1.3.1. Research and development for advanced treatments for peripheral arterial disease
  - 5.1.3.2. Growing product approvals for the treatment of peripheral arterial disease
- 5.1.4. Challenges
  - 5.1.4.1. Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Peripheral Arterial Disease Therapeutics Market, by Treatment Type

6.1. Introduction
6.2. Medications
- 6.3.1. Antihypertensives
- 6.3.2. Naftidrofuryl Oxalate
- 6.3.3. Statins
6.3. Surgical Treatments
- 6.4.1. Angioplasty
- 6.4.2. Artery Bypass Graft

7. Peripheral Arterial Disease Therapeutics Market, by Indication Stage

7.1. Introduction
7.2. Asymptomatic
7.3. Ischemic Rest Pain
7.4. Mild Claudication
7.5. Moderate/Severe Claudication
7.6. Ulcers/Gangrene

8. Peripheral Arterial Disease Therapeutics Market, by End-Users

8.1. Introduction
8.2. Hospitals
8.3. Specialty Clinics

9. Americas Peripheral Arterial Disease Therapeutics Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Peripheral Arterial Disease Therapeutics Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Peripheral Arterial Disease Therapeutics Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. Alucent Biomedical Inc.
- 13.1.3. AnGes, Inc.
- 13.1.4. AngioDynamics, Inc.
- 13.1.5. ARCA biopharma, Inc.
- 13.1.6. B. Braun SE
- 13.1.7. Becton, Dickinson and Company
- 13.1.8. BIOTRONIK SE & Co. KG
- 13.1.9. Boston Scientific Corporation
- 13.1.10. Cook Group Incorporated
- 13.1.11. Helixmith Co., Ltd.
- 13.1.12. Koninklijke Philips N.V.
- 13.1.13. LeMaitre Vascular, Inc.
- 13.1.14. Medtronic PLC
- 13.1.15. Meril Life Sciences Pvt. Ltd.
- 13.1.16. MicroPort Scientific Corporation
- 13.1.17. REVA Medical, LLC
- 13.1.18. Terumo Corporation
- 13.1.19. Venturis Therapeutics, Inc.
- 13.1.20. W. L. Gore & Associates, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing